newsfilter
← Latest News
GlobeNewswire·

Instil Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update

  • Instil Bio, Inc. reported third quarter 2026 financial results & provided a corporate update on its asset-focused development model.
  • The company's strategy involves internally developing or in-licensing programs to build a diversified portfolio of development candidates under focused subsidiaries.
  • Total cash, cash equivalents, restricted cash, marketable securities, & long-term investments stood at $67.1 million as of September 30, 2026, which is expected to fund operations through 2027.
  • Cash, cash equivalents, restricted cash, marketable securities, & long-term investments decreased from $76.3 million as of December 31, 2025, to $67.1 million in the current period.
  • In-process research & development expenses were nil for the three & nine months ended September 30, 2026, compared to $10.0 million for the nine months ended September 30, 2025.
  • Research & development expenses were $0.2 million for the three months & $1.2 million for the nine months ended September 30, 2026, down from $9.1 million & $21.2 million respectively in the prior year period.
  • General & administrative expenses were $5.8 million for the three months & $17.5 million for the nine months ended September 30, 2026, compared to corrected figures of $6.3 million & $22.7 million in 2025.
  • Restructuring & impairment charges, net, showed a $0.1 million reversal for the three months & a $1.1 million charge for the nine months ended September 30, 2026, versus nil & $16.6 million in 2025.
  • Net loss was $4.2 million for the three months & $13.0 million for the nine months ended September 30, 2026, compared to corrected figures of $13.6 million & $63.5 million in 2025.
  • Net loss per share was $0.62 for the three months & $1.92 for the nine months ended September 30, 2026, down from corrected figures of $2.01 & $9.58 in 2025.
  • Non-GAAP net loss per share was $0.48 for the three months & $1.32 for the nine months ended September 30, 2026, compared to $1.75 & $6.00 in 2025.
  • Instil corrected immaterial errors in previously issued financial statements regarding property taxes & tenant reimbursements at its Tarzana facility but confirmed no prior filings require amendment.
  • Non-GAAP financial measures were presented excluding non-cash stock-based compensation & restructuring/impairment charges to aid investor understanding.
Company
Instil Bio, Inc.
Keywords
Nasdaq:TIL, Instil Bio, Inc.